Robotic-assisted radical cystectomy with intracorporeal urinary diversion versus open: early Australian experience
Loading...
Citations
Scopus:
Altmetric:
Altmetric::
Associated Records
Authors
File Licence
Editors
Date
2018-10-01
Source Title
ANZ Journal of Surgery
Journal Title
Journal ISSN
Volume Title
Publisher
WILEY
Melbourne Authors
Affiliation
Medical Education
Clinical School (Royal Melbourne Hospital)
Surgery (RMH)
Clinical School (Royal Melbourne Hospital)
Surgery (RMH)
Document Type
Journal Article
Subject Code
Citation
Chow, K., Zargar, H., Corcoran, N. M., Costello, A. J., Peters, J. S. & Dundee, P. (2018). Robotic-assisted radical cystectomy with intracorporeal urinary diversion versus open: early Australian experience. ANZ Journal of Surgery, 88 (10), pp.1028-1032. https://doi.org/10.1111/ans.14361.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
BACKGROUND: The aim of this study was to describe our initial Australian single surgeon experience with robotic-assisted radical cystectomy (RARC) and intracorporeal urinary diversion (ICUD) and to compare the outcomes with open radical cystectomy (ORC). METHODS: Between January 2014 and June 2016, consecutive patients diagnosed with muscle invasive and high-risk non-muscle invasive bladder cancer undergoing radical cystectomy were included. Treatment modalities included either RARC with ICUD or ORC. ICUD consisted of either intracorporeal ileal conduit or orthotopic neobladder formation. Prospectively collected perioperative and oncological outcomes were analysed. RESULTS: Twenty-six RARC and 13 ORC were performed. Median operating times were 362 and 240 min for RARC and ORC, respectively (P < 0.001). Estimated blood loss for RARC was 300 mL compared with 500 mL for ORC (P = 0.01). Post-operative haemoglobin drop was less in the RARC cohort (20% versus 24%, P = 0.03). There was no statistical difference in overall 90-day complication rates (81% versus 62%, P = 0.25) and 90-day major complication rates (19% versus 23%, P = 0.67) between the RARC and ORC groups, respectively. Positive surgical margins for RARC were 4% and 8% for ORC (P = 1.0). CONCLUSION: Early results demonstrate that the safe introduction of RARC with ICUD in Australia is potentially feasible without compromising perioperative and oncological outcomes. Future randomized trial with larger numbers will be required for further analysis in the Australian setting.